These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33256086)
21. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma. Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833 [TBL] [Abstract][Full Text] [Related]
22. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Yang L; Clarke MJ; Carlson BL; Mladek AC; Schroeder MA; Decker P; Wu W; Kitange GJ; Grogan PT; Goble JM; Uhm J; Galanis E; Giannini C; Lane HA; James CD; Sarkaria JN Clin Cancer Res; 2008 Jun; 14(12):3993-4001. PubMed ID: 18559622 [TBL] [Abstract][Full Text] [Related]
23. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908 [TBL] [Abstract][Full Text] [Related]
24. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
25. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827 [TBL] [Abstract][Full Text] [Related]
26. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879 [TBL] [Abstract][Full Text] [Related]
27. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141 [TBL] [Abstract][Full Text] [Related]
28. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474 [TBL] [Abstract][Full Text] [Related]
29. 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis. Gao D; Nyalali AMK; Hou Y; Xu Y; Zhou J; Zhao W; Huang B; Li F J Mol Neurosci; 2021 Aug; 71(8):1703-1713. PubMed ID: 33400072 [TBL] [Abstract][Full Text] [Related]
30. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer. Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. Ren Y; Zhou X; Mei M; Yuan XB; Han L; Wang GX; Jia ZF; Xu P; Pu PY; Kang CS BMC Cancer; 2010 Jan; 10():27. PubMed ID: 20113523 [TBL] [Abstract][Full Text] [Related]
32. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087 [TBL] [Abstract][Full Text] [Related]
33. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway. Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302 [TBL] [Abstract][Full Text] [Related]
34. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829 [TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models. Watanabe T; Ohtani T; Aihara M; Ishiuchi S J Neurosurg; 2013 Apr; 118(4):838-45. PubMed ID: 23311938 [TBL] [Abstract][Full Text] [Related]
36. Targeting the AKT pathway in glioblastoma. McDowell KA; Riggins GJ; Gallia GL Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416 [TBL] [Abstract][Full Text] [Related]
37. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
38. MAGI3 Suppresses Glioma Cell Proliferation via Upregulation of PTEN Expression. Ma Q; Zhang Y; Meng R; Xie KM; Xiong Y; Lin S; He ZL; Tao T; Yang Y; Zhao JZ; He JQ Biomed Environ Sci; 2015 Jul; 28(7):502-9. PubMed ID: 26248734 [TBL] [Abstract][Full Text] [Related]
39. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway. Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627 [TBL] [Abstract][Full Text] [Related]
40. KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Woo SR; Ham Y; Kang W; Yang H; Kim S; Jin J; Joo KM; Nam DH Biomed Res Int; 2014; 2014():747415. PubMed ID: 25295271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]